Validation of the first commercial ELISA for type 2N von Willebrand's disease diagnosis.

Veyradier, A; Caron, C; Ternisien, C; Wolf, M; Trossaert, M; Fressinaud, E; Goudemand, J

Veyradier, A; Caron, C; Ternisien, C; Wolf, M; Trossaert, M; Fressinaud, E; Goudemand, J.

Affiliation

Veyradier A; Service d'Hématologie Biologique, Hôpital Antoine Béclère, Clamart Cedex, France. agnes.veyradier@abc.aphp.fr

Haemophilia ; 17(6): 944-51, 2011 Nov.

Article in En | MEDLINE | ID: mdl-21371195

Subject(s)

Enzyme-Linked Immunosorbent Assay/methods; Factor VIII/metabolism; von Willebrand Disease, Type 2/diagnosis; von Willebrand Factor/metabolism; Hemophilia A/diagnosis; Humans; Mutation/genetics; Reagent Kits, Diagnostic; Reference Values; Reproducibility of Results; Sensitivity and Specificity; von Willebrand Disease, Type 2/genetics; von Willebrand Diseases/diagnosis

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Factor VIII / Von Willebrand Factor / Enzyme-Linked Immunosorbent Assay / Von Willebrand Disease, Type 2 Type of study: Clinical_trials / Diagnostic_studies Limits: Humans Language: En Journal: Haemophilia Year: 2011 Document type: Article

Fulltext

XML

PubMed Links

Search on Google